Ojemda (Tovorafenib)

Ojemda (tovorafenib), a potent kinase inhibitor, is used for the treatment of patients aged six months and above diagnosed with relapsed or refractory pediatric low-grade glioma (LGG) featuring either a BRAF fusion or rearrangement or a BRAF V600 mutation.

Note: The approval for this indication is granted under accelerated approval, relying on response rate (RR) and duration of response as primary endpoints. However, ongoing approval may require further validation and characterization of clinical benefits through confirmatory trials. This accelerated pathway acknowledges the urgent need for effective treatments in this patient population while ensuring ongoing evaluation of Ojemda’s therapeutic efficacy and safety profile in pediatric low-grade glioma with BRAF alterations. 

Recommended Dosage: The recommended dosage of Ojemda based on body surface area (BSA) is 380 mg/m2 orally once weekly (the maximum recommended dosage is 600 mg orally once weekly) with or without food until there is evidence of disease progression or intolerable toxicity. Tablets should be swallowed whole with the help of water. It is not advisable to crush, chew, or cut. This medicine may be administered as an immediate-release tablet or as an oral suspension.

If a dose of Ojemda is missed by 3 days or less, take the missed dose as quickly as possible, and take the very next dose on its regularly scheduled day. If a dose is missed by more than 3 days, skip the missed dose and take the very next dose on its regularly scheduled day.

• Treatment with Ojemda 100 mg tablets can cause hepatotoxicity, including liver enzyme elevations and liver failure. Monitor liver function tests before starting treatment, regularly during treatment, and as clinically indicated. Discontinue therapy if liver dysfunction is severe or persistent.
  
• Cutaneous squamous cell carcinoma (cuSCC), including keratoacanthoma, has been reported with this treatment. Regularly monitor for skin changes, including new or worsening lesions. Promptly evaluate suspicious skin lesions and discontinue treatment if cuSCC is confirmed.
  
• Tovorafenib may increase the risk of hemorrhage, including severe and fatal events. Use caution in patients with a history of bleeding disorders or concomitant use of anticoagulants. Promptly investigate signs or symptoms of bleeding, and interrupt or discontinue therapy as appropriate.
  
• Cardiac dysfunction, including heart failure and left ventricular dysfunction, has been observed with Tovorafenib treatment. Monitor cardiac function before starting treatment and periodically during treatment. Manage cardiac dysfunction according to clinical guidelines.
  
• This therapeutic drug can prolong the QT interval, potentially leading to ventricular arrhythmias. Avoid coadministration with QT-prolonging drugs, and monitor electrolytes and electrocardiograms regularly. Correct electrolyte imbalances and consider dose interruption or reduction if QT prolongation occurs.
  
• Photosensitivity reactions, including severe cases, have been reported with Tovorafenib 100 mg. Advise patients to minimize sun exposure and use sun protection measures. Consider temporary interruption or dose reduction if severe photosensitivity reactions occur.
  
• Ojemda can cause fetal harm when administered to pregnant women. Advise females of reproductive potential to use effective contraception during treatment and for at least one month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for at least one week after the last dose.

What documents are required to import OJEMDA to India?

OJEMDA (tovorafenib) tablets/oral suspension can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable
  

Is OJEMDA available in India?

OJEMDA (tovorafenib tablets/oral suspension) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Ojemda in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.
  

OJEMDA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of OJEMDA (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Ojemda 100 mg price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the OJEMDA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Ojemda®?

Tovorafenib is a Generic Name for the trade name drug Ojemda®.

What is the Manufacturer’s Name of Ojemda®?

Ojemda® is manufactured by Day One Biopharmaceuticals, Inc.

Is Ojemda® approved by the FDA?

Yes, Ojemda® is approved by the FDA. Date of first approval: April 23, 2024.

What is the dosage and form of Ojemda® supplied?

Ojemda® is supplied as 100 mg orange, film-coated, oval, immediate-release tablets for oral use, as well as 25mg/ml white to off-white powder that forms a strawberry-flavored oral suspension. 

How often is Ojemda® taken?

Ojemda is the only once-weekly oral targeted treatment for individuals with low-grade glioma with the flexibility to be administered with or without food. This therapeutic drug can be taken conveniently from home.

What forms of Ojemda® are available for my child?

Ojemda is supplied in liquid form (oral suspension) and tablet form. If your child is prescribed this drug, you and your child’s doctor will determine which form of medication is appropriate for your child.

What are the most common side effects of Ojemda®? 

The most common side effects of Ojemda® are viral infection, rash, hair color changes, vomiting, fatigue, dry skin, headache, hemorrhage, pyrexia, constipation, nausea, upper respiratory tract infection, and dermatitis acneiform. 

How much does Ojemda® cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Ojemda 100 mg in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Ojemda®?

Ojemda tablets and oral suspension should be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F). Avoid exposure to excessive heat or moisture.

Is it safe to buy Ojemda® online in India?

Yes, one can buy Ojemda online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Ojemda® through legal channels.